Square Pharmaceuticals achieved a record net profit of Tk 20.92 billion for FY’24, a 10.26% increase year-on-year, driven by expanded distribution and sales. The company declared its highest-ever 110% cash dividend. Despite rising dollar rates impacting costs, strategic enhancements in distribution supported growth, with revenue up 12% to Tk 70 billion and NOCFPS doubling to Tk 20.90. Plans for Tk 5 billion in modernization and partnerships with local firms aim to meet rising demand, solidifying Square Pharma’s position as the second-largest market-cap firm after Grameenphone.
BIZDATAINSIGHTS
Bizdata Insights is a Market Insights, Data Intelligence and Business Advisory Platform
Our Solutions
Menu
Newsletter
Sign up for our newsletter now by entering your e-mail address and never miss out on the latest news and updates from our team!